AzTrials
AzTrials

Alopecia AreataPhase 3BRAVE-AA2NCT03899259

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

A Phase 3 study testing Baricitinib in people with Alopecia Areata, run by Eli Lilly and Company at 96 sites in 10 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA). Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Alopecia Areata
What is being tested?
Baricitinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
606 participants
Where
96 sitesin 10 countries
Study dates
8 Jul 2019to 19 Nov 2024
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent.
  • Have severe or very severe AA, as determined by all of the following:
  • Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by SALT (AA-IGA of 3 or 4) at screening and baseline.
  • No spontaneous improvement over the past 6 months.
  • Current episode of severe or very severe AA of less than 8 years. Note: participants who have severe or very severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.
  • Male or nonpregnant, nonbreastfeeding female participants.

Who cannot join

  • Primarily "diffuse" type of AA.
  • Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA.
  • Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment).

Trial locations and contacts

96 sites in 10 countries.

96 sites in 10 countries

United States33 sites
  • Great Lakes Research Group, Inc.

    Bay City, Michigan, 48706

  • Bexley Dermatology Research

    Bexley, Ohio, 43209

  • Total Skin and Beauty Dermatology Center, PC

    Birmingham, Alabama, 35205

  • Tufts Medical Center

    Boston, Massachusetts, 02111

  • New England Research Associates

    Bridgeport, Connecticut, 06606

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27516

  • Dermatology Specialists of Charlotte

    Charlotte, North Carolina, 28211

  • Clinical Research Institute of Michigan, LLC

    Chesterfield, Michigan, 48047

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106

  • Florida Academic Centers Research and Education, LLC

    Coral Gables, Florida, 33134

  • Velocity Clinical Research, Providence

    East Greenwich, Rhode Island, 02818

  • Hamzavi Dermatology

    Fort Gratiot, Michigan, 48059

  • Center For Dermatology Clinical Research, Inc.

    Fremont, California, 94538

  • Suzanne Bruce and Associates, PA

    Houston, Texas, 77056

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana, 46250

  • Dermatologists of Southwest Ohio

    Mason, Ohio, 45040

  • New Horizon Research Center

    Miami, Florida, 33165

  • Associated Skin Care Specialists

    New Brighton, Minnesota, 55112

  • Virginia Clinical Research, Inc.

    Norfolk, Virginia, 23502

  • Quest Dermatology Research

    Northridge, California, 91324

  • Qualmedica Research, LLC

    Owensboro, Kentucky, 42303

  • Northwest Dermatology Institute

    Portland, Oregon, 97210

  • Oregon Dermatology and Research Center

    Portland, Oregon, 97210

  • M3-Emerging Medical Research

    Raleigh, North Carolina, 27612

  • Dermatology and Skin Cancer Specialists

    Rockville, Maryland, 20850

  • MediSearch Clinical Trials

    Saint Joseph, Missouri, 64506

  • Progressive Clinical Research

    San Antonio, Texas, 78213

  • Kaiser Permanente Hospital

    San Francisco, California, 94118

  • Investigate MD

    Scottsdale, Arizona, 85255

  • The South Bend Clinic Center for Research

    South Bend, Indiana, 46617

  • ForCare Clinical Research

    Tampa, Florida, 33613-1244

  • Joseph J. Schwartz, M.D.

    Troy, New York, 12180

  • Vital Prospects Clinical Research Institute, P.C.

    Tulsa, Oklahoma, 74136

Other trials in United States

China15 sites
  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100020

  • Beijing Friendship Hospital Affiliate of Capital University

    Beijing, Beijing Municipality, 100050

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, 100853

  • Xiangya Hospital Central South University

    Changsha, Hunan, 410008

  • Guangdong Province Dermatology Hospital

    Guangzhou, Guangdong, 510018

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, 310014

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310052

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029

  • HuaShan Hospital Affiliated To Fudan University

    Shanghai, Shanghai Municipality, 200040

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, 200071

  • First Affiliated Hospital of Shanxi Medical University

    Taiyuan, Shanxi, 30001

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, 710004

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 212000

Other trials in China

Brazil8 sites
  • Centro de Pesquisa Sao Lucas

    Campinas, São Paulo, 13034-685

  • Hospital de Clínicas Da Universidade Estadual de Campinas

    Campinas, São Paulo, 13083-888

  • Irmandade da Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, 90050-170

  • IDERJ - Instituto de Dermatologia e Estética do Brasil

    Rio de Janeiro, Rio de Janeiro, 22470-220

  • IBPClin - Instituto Brasil de Pesquisa Clínica

    Rio de Janeiro, 22241-180

  • Faculdade de Medicina do ABC

    Santo André, São Paulo, 09060-870

  • IPITEC

    São Paulo, 01223-001

  • Servidor Público Estadual - IAMSPE - centro de estudos urológicos

    São Paulo, 04039-901

Other trials in Brazil

Japan8 sites
  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, 113-8431

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, 431-3192

  • Juntendo Tokyo Koto Geriatric Medical Center

    Koto-ku, Tokyo, 136-0075

  • Kyorin University Hospital

    Mitaka, Tokyo, 181-8611

  • Osaka City University Hospital

    Osaka, 545-8586

  • Tokyo Medical Univ. Hospital

    Shinjuku-ku, Tokyo, 160-0023

  • Yamaguchi University Hospital

    Ube, Yamaguchi, 755-8505

  • Yokohama Rosai Hospital

    Yokohama, Kanagawa, 222-0036

Other trials in Japan

Argentina7 sites
  • Buenos Aires Skin

    Buenos Aires, Buenos Aires F.D., 1055

  • Fundacion Respirar

    Buenos Aires, Ciudad Autonoma Buenos Aires, C1426ABO

  • Stat Research

    CABA, Buenos Aires, C1023AAB

  • Instituto de Neumonología y Dermatología

    Capital Federal, Buenos Aires, 1425

  • Centro de Investigaciones Metabólicas (CINME)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, 1027

  • Parra Dermatología

    Mendoza, 5500

  • Centro de Investigaciones Médicas Tucuman

    SAN M. de Tucuman, Tucumán Province, T4000AXL

Other trials in Argentina

Australia7 sites
  • Clinical Trials SA Pty Ltd

    Campbelltown, South Australia, 5073

  • Skin Health Institute Inc.

    Carlton, Victoria, 3053

  • Fremantle Dermatology

    Fremantle, Western Australia, 6160

  • Sinclair Dermatology

    Melbourne, Victoria, 3002

  • Woden Dermatology

    Phillip, Australian Capital Territory, 2606

  • Skin & Cancer Foundation Australia

    Westmead, New South Wales, 2045

  • Veracity Clinical Research Pty Ltd

    Woolloongabba, Queensland, 4102

Other trials in Australia

Israel7 sites
  • Emek Medical Center

    Afula, Northern District, 1834111

  • Soroka Medical Center

    Beersheba, Southern District, 8410101

  • Rambam Medical Center

    Haifa, Northern District, 3109601

  • Hadassah Medical Center

    Jerusalem, Jerusalem, 9112001

  • Rabin Medical Center

    Petah Tikva, Central District, 4941492

  • Sheba Medical Center

    Ramat Gan, Central District, 5262100

  • Sourasky Medical Center

    Tel Aviv, Tell Abīb, 6423906

Other trials in Israel

South Korea6 sites
  • Soonchunhyang University Bucheon Hospital

    Bucheon-si, Gyeonggi-do, 14584

  • Dankook University Hospital

    Cheonan, Chungcheongnam-do, 31116

  • Boramae Medical Center

    Dongjak-gu, Seoul-teukbyeolsi [Seoul], 07061

  • Kyunghee University Hospital at Gangdong

    Seoul, Seoul-teukbyeolsi [Seoul], 134-090

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722

  • Ajou University Hospital

    Suwon, Gyeonggi-do, 16499

Other trials in South Korea

Taiwan4 sites
  • Chung Shan Medical University Hospital

    Taichung, Taichung, 402

  • National Cheng Kung University Hospital

    Tainan, 704

  • National Taiwan University Hospital

    Taipei, 10002

  • Chang Gung Medical Foundation-Linkou Branch

    Taoyuan, 333

Other trials in Taiwan

Puerto Rico1 site
  • Clinical Research Puerto Rico

    San Juan, 00909

Other trials in Puerto Rico

About this study

Official title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Conditions
Alopecia Areata
Being tested
Baricitinib, Placebo
Medical subject headings
Alopecia Areata

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BaricitinibDrug

    Also called LY3009104

    Administered orally

  • PlaceboDrug

    Administered orally

Study groups in NCT03899259
Study groupRoleWhat they receive
PlaceboPlacebo comparatorParticipants received two placebo tablets matched to baricitinib, administered orally once daily (QD) to maintain the blind.
Receives: Drug: Placebo
2 mg BaricitinibExperimentalParticipants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.
Receives: Drug: Baricitinib
4 mg BaricitinibExperimentalParticipants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.
Receives: Drug: Baricitinib
Placebo/ PlaceboPlacebo comparatorParticipants who received two placebo tablets administered orally QD in Period 1 continue to receive the same placebo in Period 2.
Receives: Drug: Placebo
Placebo/ 2-mg BaricitinibExperimentalParticipants who received two placebo at Period 1 switched to receive 2 mg Baricitinib dose administered orally QD in Period 2.
Receives: Drug: Baricitinib
Placebo/ 4-mg BaricitinibExperimentalParticipants who received two placebo at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2.
Receives: Drug: Baricitinib
2-mg Baricitinib/ 2-mg BaricitinibExperimentalParticipants who received 2 mg Baricitinib at Period 1 continued to receive same 2 mg Baricitinib dose administered orally QD in Period 2.
Receives: Drug: Baricitinib
2-mg Baricitinib/ 4-mg BaricitinibExperimentalParticipants who received 2 mg Baricitinib at Period 1 switched to receive 4 mg Baricitinib dose administered orally QD in Period 2.
Receives: Drug: Baricitinib
4-mg Baricitinib/ PlaceboExperimentalParticipants who received 4 mg Baricitinib at Period 1 switched to receive Placebo administered orally QD in Period 2.
Receives: Drug: Placebo
4-mg Baricitinib/ 2-mg BaricitinibExperimentalParticipants who received 4 mg Baricitinib at Period 1 switched to receive 2 mg Baricitinib administered orally QD in Period 2.
Receives: Drug: Baricitinib
4-mg Baricitinib/ 4-mg BaricitinibExperimentalParticipants who received 4 mg Baricitinib at Period 1 continued to receive same 4 mg Baricitinib administered orally QD in Period 2.
Receives: Drug: Baricitinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20

    The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes.

    Measured: Week 36

Secondary outcomes (13)
  1. Percent Change From Baseline in SALT Score at Week 36

    SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Least Squares Mean (LSM) was calculated using analysis of covariance (ANCOVA) with geographic region duration of current episode at baseline (< 4 years versus ≥4 years), treatment group, and baseline value in the model.

    Measured: Baseline, Week 36

  2. Percentage of Participants Achieving 50% Improvement of Severity of Alopecia Tool (SALT50)

    SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. SALT50 indicates at least a 50 % improvement from baseline in the SALT score.

    Measured: Week 12

  3. Percentage of Participants With Patient-Reported Outcome (PRO) for Scalp Hair Assessment Score of 0 or 1 With a ≥2-point Improvement From Baseline Among Participants With a Score of ≥3 at Baseline

    PRO is an assessment of the particpant's current extent of scalp involvement. It is comprised of 5 category response options: 0= No missing hair (0% of my scalp is missing hair; I have a full head of hair); 1 = A limited area (1% to 20% of my scalp is missing hair); 2 = A moderate area (21% to 49% of my scalp is missing hair); 3 = A large area (50% to 94% of my scalp is missing hair); and 4 = Nearly all or all (95% to 100% of my scalp is missing hair).

    Measured: Week 36

  4. Time for Participants to Achieve SALT ≤ 20 at Week 36.

    The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Kaplan-Meier method was used for analysis. Time for participants to achieve salt ≤ 20 at week 36 were reported in this outcome measure.

    Measured: Week 36

  5. Percentage of Participants Achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥2 at Baseline)

    ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.

    Measured: Week 36

  6. Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥2 at Baseline)

    ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.

    Measured: Week 36

  7. Percentage of Participants Achieving Patient-Reported Outcome (PRO) Measure for EB 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure for EB ≥2 at Baseline)

    PRO is an assessment of the participant's current appearance of eyebrows. It is comprised of 4 category response options: 0 = I have full EB on each eye; 1= I have a minimal gap(s) or a minimal amount of thinning in at least 1 of my EB; 2 = I have a large gap(s) or a large amount of thinning in at least 1 of my EB; and 3 = I have no or barely any EB hairs.

    Measured: Week 36

  8. Percentage of Participants Achieving PRO Measure for EL 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With PRO Measure EL ≥2 at Baseline)

    PRO assessment of the participant's current appearance of EL. It is comprised of 4 category response options: 0 = I have full EL on each eyelid; 1 = I have a minimal gap or minimal gaps along the eyelids; 2 = I have a large gap or large gaps along the eyelids; and 3 = I have no or barely any EL hair.

    Measured: Week 36

  9. Change From Baseline in Skindex-16 Alopecia Areata (AA) Symptoms Domain Score

    Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life.

    LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.

    Measured: Baseline, Week 36

  10. Change From Baseline in Skindex-16 AA Emotions Domain Score at Week 36

    Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life.

    LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.

    Measured: Baseline, Week 36

  11. Change From Baseline in Skindex-16 AA Functioning Domain Score at Week 36

    Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life.

    LS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.

    Measured: Baseline, Week 36

  12. Mean Change From Baseline in Hospital Anxiety Depression Scale (HADS) Anxiety Score at Week 36

    The HADS is a 14-item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (for example, 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression.

    LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.

    Measured: Baseline, Week 36

  13. Mean Change From Baseline in HADS Depression Score at Week 36

    The HADS is a 14-item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (for example, 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression.

    LS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.

    Measured: Baseline,Week 36

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Apr 2019
  2. Study start8 Jul 2019
  3. Primary completion24 Jan 2021
  4. Study completion19 Nov 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
606 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03899259
Sponsor's protocol ID
16978
Other IDs
I4V-MC-JAIR
Acronym
BRAVE-AA2
Status last verified
Mar 2026
First submitted
1 Apr 2019
Last updated
7 Apr 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Publications

  • Vleugels RA, Piraccini BM, Mesinkovska N, Mostaghimi A, Shimomura Y, Sontag A, McSwiney F, Somani N, Pandey H, Denning K, King B. Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2. Dermatol Ther (Heidelb). 2026 Oct 2. doi: 10.1007/s13555-026-01886-9. Online ahead of print.

    PubMed 42825995
  • King B, Mostaghimi A, Shimomura Y, Piraccini BM, Blume-Peytavi U, Sontag A, Dutronc Y, Denning K, Kolodsick J, Lu X, Srivastava A, Sinclair R. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment. Am J Clin Dermatol. 2025 Jul;26(4):611-622. doi: 10.1007/s40257-025-00932-0. Epub 2025 Apr 11.

    PubMed 40214720
  • Craiglow B, Lee YW, Vano-Galvan S, Egeberg A, Dutronc Y, Durand F, Pierce E, Yu G, Chen YF, Mostaghimi A. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib. Dermatol Ther (Heidelb). 2024 Jul;14(7):1959-1968. doi: 10.1007/s13555-024-01208-x. Epub 2024 Jun 21.

    PubMed 38904749
  • Senna MM, Kwon O, Piraccini BM, Sinclair R, Ball S, Ding Y, Chen YF, Dutronc Y, King B. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatol Ther (Heidelb). 2023 Dec;13(12):3209-3220. doi: 10.1007/s13555-023-01063-2. Epub 2023 Nov 22.

    PubMed 37991697
  • Ko JM, Mayo TT, Bergfeld WF, Dutronc Y, Yu G, Ball SG, Somani N, Craiglow BG. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials. JAMA Dermatol. 2023 Sep 1;159(9):970-976. doi: 10.1001/jamadermatol.2023.2581.

    PubMed 37556146
  • Piraccini BM, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen YF, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. J Dermatolog Treat. 2023 Dec;34(1):2227299. doi: 10.1080/09546634.2023.2227299.

    PubMed 37381691
  • Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1.

    PubMed 36855020
  • King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, Passeron T, Holzwarth K, Dutronc Y, McCollam J, Yang FE, Stanley S, Wu WS, Sinclair R. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023 Feb 10;188(2):218-227. doi: 10.1093/bjd/ljac059.

    PubMed 36763878
  • King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26.

    PubMed 35334197

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Baricitinib in people with Alopecia Areata, run by Eli Lilly and Company at 96 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 96 sites in United States, China, Brazil, Japan, Argentina and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 14 May 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 (time frame: Week 36). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03899259, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in